Navigation Links
Comparing Psoriasis Treatments

A new study shows two common treatments for psoriasis -- methotrexate and cyclosporine -- are equally effective in relieving symptoms of the disease. //

Researchers in Amsterdam studied nearly 90 patients with moderate-to-severe psoriasis. Half of the patients were given methotrexate, and the other half were treated with cyclosporine. Researchers evaluated the side effects and effectiveness of each drug. They also recorded the time patients were in remission and assessed their quality of life. None of the participants had previously been treated with methotrexate or cyclosporine.

Results of the study show the overall response rate for both drugs was more than 90 percent. Seventeen patients in the methotrexate group and 14 patients in the cyclosporine group reached nearly complete remission. Twenty-six patients in the methotrexate group and 30 patients in the cyclosporine group achieved partial remission. However, after 16 weeks of treatment, no significant difference in overall effectiveness was seen between the two groups.

More than 100 patients in the methotrexate group and more than 150 patients in the cyclosporine group reported side effects. More patients in the methotrexate group reported nausea, and patients in the cyclosporine group were more likely to report headaches. There were no significant reported differences in quality of life between the two groups.

Authors of the study say the overall effectiveness of methotrexate is similar to that of cyclosporine. They conclude, "Differences between the treatments in terms of side effects, long-term adverse effects, ease of administration, and costs can be used to guide treatment decisions in individual cases."
'"/>




Page: 1

Related medicine news :

1. Comparing Breast surgery techniques
2. Comparing heart disease treatments
3. New and unique treatment for Psoriasis patients
4. Psoriasis Increases Cancer Risk
5. Help for Psoriasis
6. Managing Patients With Psoriasis
7. Effective Treatment Option For Psoriasis
8. Smoking Aggravates Psoriasis
9. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
10. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
11. Psoriasis raises risk for heart attack
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: